|D013315||Stress, Psychological NIH||0.18|
|D001008||Anxiety Disorders NIH||0.16|
There is one clinical trial.
This is a feasibility study taking place at The Ottawa Hospital (TOH), Hôpital Montfort, and Queensway Carleton Hospital that seeks to evaluate the impact of the COVID-19 pandemic on family member bereavement and study the effect of virtual support groups on reducing risk of developing Severe Grief Reaction (SGR). This project is inviting family members of deceased patients at either of the three before mentioned sites to enroll in this study.
Description: This tool, used to detect pathological grief, has a total of 19 questions. Respondents rate the frequency with which they experience each item on a 5-point scale (0-4), ranging from "never" to "always." Respondents with ICG-r scores greater than 25 are significantly more impaired in social, general, mental and physical health functioning and in bodily pain than those with ICG-r scores less than or equal to 25. Higher scores result in higher likelihood of CG.Measure: The Inventory for Complicated Grief-revised (ICG-r) score at 6 months post-death Time: at 6 months post-death
Description: Participating FMs will have a repeat ICG-r assessment (as described for primary outcome #1) at 12 months post-death.Measure: The Inventory for Complicated Grief-revised (ICG-r) score at 12 months post-death Time: at 12 months post-death
Description: The relative changes in ICG scores between 6 and 12 months of FMs who participate in the VSGs vs. those who do not will be compared as a measure of the efficacy of the VSG interventionMeasure: Change in ICG-r score from 6 months to 12 months post-death Time: at 12 months post-death relative to 6 months post-death
Description: Interviews with family member participants upon completion of virtual support group intervention to determine usefulness for family members' bereavement process. This is a qualitative method of data collection so there is no scale or scoreMeasure: Qualitative Interviews Post-Virtual Support Group Time: Through study completion, an average of 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports